Summary by Moomoo AI
Knight Therapeutics Inc., a Canadian pharmaceutical company, and its subsidiary, Knight Therapeutics International S.A., based in Uruguay, have jointly filed an amended Schedule 13G/A with the SEC, disclosing a significant stake in 60 Degrees Pharmaceuticals. The filing, dated May 3, 2024, indicates that Knight Therapeutics Inc. has transferred 1,153,897 shares of common stock from its subsidiary, resulting in direct beneficial ownership of 9.97% of 60 Degrees Pharmaceuticals' issued and outstanding shares as of April 1, 2024. The shares were previously held directly by Knight Therapeutics International S.A. The filing asserts that the shares are not intended for the purpose of changing or influencing the control of 60 Degrees Pharmaceuticals, nor in connection with any transaction having such purpose or effect.